A targeted next-generation sequencing panel for identification of clinically relevant mutation profiles in solid...

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Targeted next-generation sequencing (NGS) with multigene panels is crucial for cancer genomic analysis.
• Outsourcing NGS assays leads to long turnaround times (approx. 3 weeks), delaying clinical decisions.

Purpose of the Study:

• To develop and validate an efficient oncopanel for comprehensive cancer gene analysis.
• To reduce the turnaround time for genomic profiling in cancer patients.

Main Methods:

• Developed an oncopanel targeting 61 cancer-associated genes.
• Validated the assay using next-generation sequencing on 43 diverse samples.
• Evaluated performance metrics including repeatability, reproducibility, sensitivity, specificity, precision, and accuracy.

Main Results:

• The assay detected 794 mutations, including all 92 known variants.
• Achieved high performance: 99.99% repeatability, 99.98% reproducibility, 98.23% sensitivity, and 99.99% specificity.
• Reduced average turnaround time to 4 days, identifying actionable mutations in key cancer genes.

Conclusions:

• The developed oncopanel is a sensitive, high-throughput assay suitable for routine clinical testing.
• The significantly shorter turnaround time can enhance patient care through timely, personalized interventions.